Business Context and Reporting Period
This Form 8-K Current Report from Avalo Therapeutics, Inc. (AVTX) covers the period ending September 29, 2025. The filing primarily announces the appointment of Taylor Boyd as Chief Business Officer, effective October 1, 2025.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Base Salary: $465,000 annually.
- Target Bonus: Up to 40% of base salary (payable in cash or immediately vested equity).
- Inducement Grant: Stock option to purchase 275,000 shares of common stock.
- Vesting Schedule: 25% on the first anniversary, with the remainder vesting in equal monthly installments over the following three years.
- Exercise Price: Equal to the closing price of common stock on the Grant Date (October 1, 2025).
Material Changes
The material change reported is the addition of a senior executive to the management team. Taylor Boyd brings nearly 15 years of experience in biotech business development and investment banking, including roles at Abzena Limited and Longboard Pharmaceuticals (which was acquired by Lundbeck for $2.6 billion).
Outlook, Risks, and Contingencies
Severance Provisions: In the event of termination without Cause or for Good Reason, Mr. Boyd is entitled to:
- Accrued salary and benefits.
- Unpaid prior year bonus and prorated current year bonus.
- Severance pay of nine months' base salary (extended to 12 months if termination occurs within six months of a Change in Control).
- Full vesting of outstanding options with a six-month exercise window.
- Up to 12 months of COBRA premium payments.
Restrictive Covenants: Severance benefits are contingent upon the execution of a release of claims and compliance with perpetual confidentiality, non-disparagement, and 12-month post-employment non-competition and non-solicitation covenants.
Investor Verification Checklist
- Verify the closing stock price on October 1, 2025, to determine the exercise price of the 275,000 share option grant.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Change in Control."
- Assess the impact of the new executive's background on the company's strategic pipeline and potential M&A activity.
- Monitor future filings for the actual grant date confirmation and any subsequent equity dilution.